Weekly Report: what happened at RDY last week (0219-0223)?
Weekly Report · 1d ago
Novo to face Wegovy competition in India as local versions loom: Reuters
Several Indian drugmakers already working on their version of Novo Nordisk's Wegovy. The Danish drugmaker has yet to launch WegovY in India. Novo to face competition in India as local versions loom: Reuters. The company's WeGovy patents are expected to expire in 2026 in China and 2032 in the U.S.
Seeking Alpha · 4d ago
Global Access to Weight-Loss Treatments: Indian Pharma Giants Eye Affordable Wegovy Alternatives Amid Rising Demand
Novo Nordisk A/S plans to introduce Wegovy in India by 2026. Indian drugmakers are aggressively pursuing the development of generic versions of the weight-loss drug. The patents for WegovY are set to expire in various regions between 2026 and 2032.
Benzinga · 4d ago
Weekly Report: what happened at RDY last week (0212-0216)?
Weekly Report · 02/19 09:06
Coya Therapeutics In Catbird Seat Following Dr. Reddy's Licensing Deal
Coya Therapeutics has strengthened its strategic positioning with a licensing deal with Dr. Reddy's. The company has expanded its pipeline and is in a strong position for upcoming clinical success and potential regulatory approval. Coya has been a standout in clinical trials for ALS and Alzheimer's disease.
Seeking Alpha · 02/13 13:25
Weekly Report: what happened at RDY last week (0205-0209)?
Weekly Report · 02/12 09:06
Why Doctor Reddy's (RDY) is a Top Momentum Stock for the Long-Term
NASDAQ · 02/05 14:50
Weekly Report: what happened at RDY last week (0129-0202)?
Weekly Report · 02/05 09:06
Dr. Reddy's (RDY) Q3 Earnings and Revenues Surpass Estimates
NASDAQ · 02/01 14:03
Dr. Reddy's Laboratories Reaches Analyst Target Price
NASDAQ · 02/01 13:13
Dr. Reddy's GAAP EPS of $0.99, revenue of $867M
Seeking Alpha · 01/30 11:20
Dr Reddy's Laboratories: Q3 Earnings Insights
Dr Reddy's Laboratories reported its Q3 earnings of $0.99 on January 30, 2024. The company beat estimates by 25.32%. Revenue for the quarter was up $42.39 million from the same period last year. Last quarter the company beat on EPS by $1.23.
Benzinga · 01/30 10:50
Dr Reddy's Laboratories Q3 EPS $0.99 Beats $0.79 Estimate, Sales $866.64M Beat $825.86M Estimate
Dr Reddy's Laboratories reported quarterly earnings of $0.99 per share. The company reported quarterly sales of $866.64 million. This is a 5.10 percent increase over sales of the same period last year. The quarterly earnings beat the analyst consensus estimate by 25.7 percent.
Benzinga · 01/30 10:46
Dr. Reddy's Q3 2024 Earnings Preview
Dr. Reddy's is scheduled to announce Q3 2024 earnings results on Tuesday, January 30th, before market open. The consensus EPS Estimate is $0.80 and the consensus revenue estimate is $831.91M. The company is expected to report its results for the quarter.
Seeking Alpha · 01/29 15:34
Webull provides a variety of real-time RDY stock news. You can receive the latest news about Dr Reddys Labs through multiple platforms. This information may help you make smarter investment decisions.
About RDY
Dr. Reddy’s Laboratories Limited is an India-based global pharmaceutical company. The Company offers a portfolio of products and services, including active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC). Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. The Company’s segments include Pharmaceutical Services and Active Ingredients, Global Generics, and Others. The Pharmaceutical Services and Active Ingredients segment primarily consists of the Company’s business of manufacturing and marketing APIs and intermediates. The Global Generics segment consists of the Company’s business of manufacturing and marketing prescription and OTC finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics).